Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic intravitreal ranibizumab for prevention of wet age-related macular degeneration in the fellow eye
ACTRN12614000511639Phase 4Not yet recruiting
- Sponsor
- El Gawhara Eye Center
- Start
- Jun 2014
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of ranibizumab in exudative macular degeneration (2 arms), sponsored by El Gawhara Eye Center. Primary endpoint: Survival of the fellow eye from wet AMD. Planned start Jun 2014; status: not yet recruiting.
02
Drugs
ranibizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on ACTRN12614000511639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12614000511639.